Brief: Innate Pharma: First Patient Dosed In Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

Innate Pharma SA

23/10/2020 06:13

Oct 23 (Reuters) - Innate Pharma SA  IPH.PA :
    * FIRST PATIENT DOSED IN MONALIZUMAB PHASE 3 CLINICAL TRIAL
TRIGGERS $50M PAYMENT FROM ASTRAZENECA
    * DOSING OF FIRST PATIENT IN THIS TRIAL HAS TRIGGERED A $50
MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO INNATE.
    * $50 MILLION MILESTONE PAYMENT FORTIFIES OUR CASH POSITION
THROUGH END OF 2022 - CEO

Source text for Eikon:  ID:nGNX9mphx5 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))